Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries. Uncontrolled, Open-label Phase 3 Study
Conditions
Interventions
IC51
IC51
+1 more
Locations
10
United States
Tampa Clinical Research Inc.
Tampa, Florida, United States
Passport Health
Baltimore, Maryland, United States
Boston Medical Center
Boston, Massachusetts, United States
Bronx Lebanon Hospital Center
New York, New York, United States
Dr. Deb - The Travel Doctor
Brisbane, Queensland, Australia
Travel Doctor - TMVC Australia
Melbourne, Victoria, Australia
Start Date
January 1, 2010
Primary Completion Date
August 1, 2013
Completion Date
August 1, 2013
Last Updated
June 30, 2020
NCT07477015
NCT05586581
NCT06079294
NCT07133113
NCT04561557
NCT05777499
Lead Sponsor
Valneva Austria GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions